Search Results for: ERBB2

August 11, 2018August 11, 2018

Rates of ERBB2 Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-amplified Acral Melanoma.

Melanoma Literature

Publication date: Aug 09, 2018 Patients with BRAF V600-wild type melanoma whose tumors progress on checkpoint inhibition currently have limited therapeutic options, and additional rational treatment targets are needed. ERBB2 ... Read more

June 27, 2018June 27, 2018

Targeting ERBB2 mutations in solid tumors: biological and clinical implications.

Melanoma Literature

Publication date: Jun 25, 2018 Preclinical data have shown that ERBB2 activating mutations are responsive to HER2 tyrosine kinase inhibitors. The aim of this study is to characterize the landscape ... Read more

June 22, 2019June 22, 2019

Retinal texture biomarkers may help to discriminate between Alzheimer’s, Parkinson’s, and healthy controls.

Parkinson's Disease Literature

Publication date: Apr 03, 2019 A top priority in biomarker development for Alzheimer’s disease (AD) and Parkinson’s disease (PD) is the focus on early diagnosis, where the use of the ... Read more

June 20, 2019June 20, 2019

Analysis of patient-specific stimulation with segmented leads in the subthalamic nucleus.

Parkinson's Disease Literature

Publication date: Dec 21, 2018 Segmented deep brain stimulation leads in the subthalamic nucleus have shown to increase therapeutic window using directional stimulation. However, it is not fully understood how ... Read more

June 19, 2019June 19, 2019

Gastrodin protects dopaminergic neurons via insulin-like pathway in a Parkinson’s disease model.

Parkinson's Disease Literature

Publication date: Jun 17, 2019 Recently, the use of traditional Chinese medicine (TCM) has become more generally accepted, including by the Food and Drug Administration. To expand the use of ... Read more

June 19, 2019June 19, 2019

Identification of N-linked glycans as specific mediators of neuronal uptake of acetylated α-Synuclein.

Parkinson's Disease Literature

Publication date: Jun 18, 2019 Cell-to-cell transmission of toxic forms of α-Synuclein (αS) is thought to underlie disease progression in Parkinson disease. αS in humans is constitutively N-terminally acetylated (αSacetyl), ... Read more

June 17, 2019June 17, 2019

Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers.

Melanoma Literature

Publication date: Apr 03, 2019 Melanoma is a highly aggressive tumor with a strong dependence on intracellular signaling pathways. Almost half of all melanomas are driven by mutations in the ... Read more

June 17, 2019June 17, 2019

Uses for humanised mouse models in precision medicine for neurodegenerative disease.

Parkinson's Disease Literature

Publication date: Jun 15, 2019 Neurodegenerative disease encompasses a wide range of disorders afflicting the central and peripheral nervous systems and is a major unmet biomedical need of our time. ... Read more

June 13, 2019June 13, 2019

Naptulomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Melanoma News

Publication date: Jun 12, 2019 This is a dose escalation (Phase 1b) and cohort expansions (Phase 2) study to assess the safety and tolerability of a combination of Nap with ... Read more

June 6, 2019June 6, 2019

Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease.

Huntington's Disease Literature

Publication date: Jun 05, 2019 Huntington disease is a neurodegenerative condition for which there is no cure to date. Activation of AMP-activated protein kinase has previously been shown to be ... Read more